Latest Advances

  • Condition: Acute Myeloid Leukemia (AML)
  • Journal: Medicine
  • Treatment Used: Intermediate Dose (ID) Cytarabine
  • Number of Patients: 52
  • Published —
This study investigated the toxic effects of a single-intermediate dose (ID) cytarabine in patients with acute myeloid leukemia (AML) after complete remission (CR).
  • Condition: Relapse or Refractory (R/R) FLT3 Positive Acute Myeloid Leukemia (AML)
  • Journal: Leukemia research
  • Treatment Used: Tyrosine Kinase Inhibitors (TKIs) vs. Conventional Therapy
  • Number of Patients: 49
  • Published —
This study evaluated tyrosine kinase inhibitors (TKIs) versus conventional therapy in the treatment of patients with relapse or refractory (R/R) FLT3 positive acute myeloid leukemia (AML).
  • Condition: Older Patients with Acute Myeloid Leukemia (AML)
  • Journal: The New England journal of medicine
  • Treatment Used: Oral Azacitidine Maintenance Therapy
  • Number of Patients: 472
  • Published —
This study evaluated the effectiveness of oral azacitidine maintenance therapy for older patients with acute myeloid leukemia (cancer of the myeloid line of blood cells; AML).
  • Condition: Adults with Acute Myeloid Leukemia (AML)
  • Journal: Hematology. American Society of Hematology. Education Program
  • Treatment Used: Chemotherapy and Supportive Care
  • Number of Patients: 0
  • Published —
This article discusses the outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings
  • Condition: Acute Myeloid Leukemia
  • Journal: American journal of hematology
  • Treatment Used: Venetoclax with Decitabine versus Intensive Chemotherapy
  • Number of Patients: 170
  • Published —
The study compared the outcomes between venetoclax with decitabine versus intensive chemotherapy for treating acute myeloid leukemia.
  • Condition: Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
  • Journal: Hematology (Amsterdam, Netherlands)
  • Treatment Used: Venetoclax (VEN) in Combination with Hypomethylating Agents (HMAs)
  • Number of Patients: 1059
  • Published —
This study evaluated the effectiveness and adverse effects of venetoclax (VEN) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  • Condition: Myeloid Leukemia with Down Syndrome (ML-DS)
  • Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
  • Treatment Used: Chemotherapy
  • Number of Patients: 0
  • Published —
This article discusses the treatment strategy for patients wit myeloid leukemia with Down syndrome (ML-DS).
  • Condition: Elderly Patients with Acute Myeloid Leukemia (AML)
  • Journal: Zhongguo shi yan xue ye xue za zhi
  • Treatment Used: Low-Intensity Traditional Chemotherapy
  • Number of Patients: 67
  • Published —
This study investigated the effectiveness of low-intensity traditional chemotherapy for elderly patients with acute myeloid leukemia (cancer of the blood and bone marrow; AML).
  • Condition: Senile Patients with High-Risk Acute Myeloid Leukemia (AML)
  • Journal: Zhongguo shi yan xue ye xue za zhi
  • Treatment Used: Decitabine Combined with Reduced FLAG Regimen
  • Number of Patients: 12
  • Published —
This study evaluated the effectiveness and adverse reactions of decitabine combined with reduced FLAG regimen in senile (loss of cognitive abilities associated with old age) patients with high-risk acute myeloid leukemia (type of blood cancer; AML).
  • Condition: Clostridioides Difficile Infections (CDI) in Patients with Acute Myeloid Leukemia (AML) Undergoing Intensive Induction Chemotherapy
  • Journal: Annals of hematology
  • Treatment Used: Carbapenems and Glycopeptides
  • Number of Patients: 415
  • Published —
This study analyzed the incidence of Clostridioides difficile infections (CDI) in patients with acute myeloid leukemia (AML) undergoing intensive induction chemotherapy.
  • Condition: Acute Myeloid Leukemia
  • Journal: The Lancet. Haematology
  • Treatment Used: 10-day Decitabine with Venetoclax
  • Number of Patients: 168
  • Published —
The study researched the safety and effectiveness of 10-day decitabine with venetoclax for acute myeloid leukemia.
  • Condition: Relapsed Acute Myeloid Leukemia
  • Journal: Medicine
  • Treatment Used: Gemtuzumab Ozogamicin Monotherapy before Stem Cell Infusion
  • Number of Patients: 1
  • Published —
This case report describes a patient with relapsed acute myeloid leukemia that was treated using a gemtuzumab ozogamicin monotherapy before undergoing a stem cell infusion.
Showing 1-12 of 327